Physician profile
Ajith Kumar Potluri
NPI 1194791392
$15,811.43
in general payments reported to CMS, 2019-2025
34 companies · $3,331 in 2025
The $3,331 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $1,051 · 2021: $1,303 · 2022: $2,443 · 2023: $3,319 · 2024: $2,899 · 2025: $3,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,469 · Education: $78.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,469.30 |
| Education | $78.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,372.30 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,348.39 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,987.12 | 2021-2025 | |
| Alkermes, INC. | $1,805.77 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $964.02 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Corium, LLC | $925.12 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $851.16 | 2019-2025 | Trintellix |
| Lundbeck LLC | $567.24 | 2019-2025 | Rexulti |
| Almatica Pharma LLC | $455.01 | 2021-2025 | Loreev Xr, Gralise |
| Bausch Health US, LLC | $436.82 | 2019-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $348.92 | 2019-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $344.34 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $319.95 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Axsome Therapeutics, INC. | $297.86 | 2022-2025 | Auvelity |
| Indivior INC. | $258.45 | 2019-2024 | Sublocade |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $222.79 | 2019-2020 | |
| Neos Therapeutics, LP | $178.10 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $162.04 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $161.45 | 2019-2025 | Ingrezza |
| Allergan, INC. | $157.04 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $135.38 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $80.48 | 2022-2024 | Quviviq |
| Adlon Therapeutics L.P. | $74.78 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $55.36 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $46.32 | 2019 | |
| Tempus Ai, INC | $45.11 | 2024 | |
| Eisai INC. | $42.98 | 2020-2021 | |
| Noven Therapeutics, LLC | $41.29 | 2021-2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $28.42 | 2025 | Jornay Pm |
| Lilly USA, LLC | $26.47 | 2025 | Kisunla |
| Acadia Pharmaceuticals INC | $20.71 | 2023 | Nuplazid |
| Neuronetics, INC. | $17.12 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.75 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $16.37 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajith Potluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.